Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Beijing Gene Key Life Technology Co. Ltd. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This prosecution involves 1 distinct examiner and 1 distinct art unit. The data indicates a concentrated current application process, with all pending activity focused on a single technical review.
MOSELEY II, NELSON B is the busiest examiner for the portfolio, with 1 busiest examiner pending office action. This examiner is responsible for the 1 pending office action currently active for the company. Since the company has 1 distinct examiner and 1 distinct art unit involved, the prosecution strategy is presently focused on the requirements of this specific examiner. The outcome of the company's current efforts at the USPTO depends on the evaluation of this 1 pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOSELEY II, NELSON B | 1 | 67.9% | +41.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18559529 | CAR-iNKT CELL TECHNOLOGY EFFECTIVE IN KILLING CHOLANGIOCARCINOMA | MOSELEY II, NELSON B | — |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18559529 | CAR-iNKT CELL TECHNOLOGY EFFECTIVE IN KILLING CHOLANGIOCARCINOMA | MOSELEY II, NELSON B | 1642 | §103 | Non-Final OA | — | Pending | Nov 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBeijing Gene Key Life Technology Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Nelson B Moseley II has the most, with 1 of Beijing Gene Key Life Technology Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
